Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis
Neurofibromatosis sort 1 nonetheless lacks established therapy choices geared toward controlling the development of neurofibromas in addition to efficient remedy for the neurogenic itch related to the illness. We report the case of a 30-year-old Caucasian lady with sort 1 neurofibromatosis coexisting with extreme refractory atopic dermatitis. Dupilumab, a novel anti-IL-Four receptor alpha monoclonal antibody, the primary biologic agent...